ERVW-1 and myeloid sarcoma: A recent clinical trial showed that anti-pathogenic human endogenous retrovirus type W (pHERVW) envelope protein (ENV)-mediated microglial polarization exerts neuroprotective effects in MS[47] (see Table 2).